Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NCNA) is a clinical-stage biopharmaceutical company pioneering ProTide technology to develop enhanced cancer therapeutics. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and scientific advancements related to NuCana's innovative approach to overcoming chemotherapy resistance.
Key resources include: Press releases detailing clinical progress, analyses of pipeline candidates for solid tumors, and updates on phosphoramidate chemistry applications. Users will find verified information on drug safety profiles, trial designs, and strategic collaborations.
Regular updates cover:
- Phase I-III clinical trial results
- Regulatory submissions and FDA communications
- Scientific conference presentations
- Intellectual property developments
Bookmark this page for structured access to NuCana's latest advancements in reengineering conventional chemotherapy agents through proprietary nucleotide analog technology. Check back for objective reporting on innovations designed to improve intracellular drug activation in cancer cells.
NuCana plc (NASDAQ: NCNA) presented two significant posters at the AACR Annual Meeting on April 14-19, 2023, showcasing its investigational drug NUC-7738. The first study demonstrated a reduction in soluble and exosomal PD-L1 in melanoma cell lines and patients, indicating potential as an immune sensitizer in combination with pembrolizumab. The second study illustrated NUC-7738's ability to decrease glutaminase GAC isoform in cancer tissues, suggesting anti-cancer activity in highly metabolic tumors. CEO Hugh S. Griffith expressed optimism about NUC-7738's mechanisms of action and ongoing clinical studies, particularly its combination therapy approach. NuCana aims to enhance treatment outcomes for cancer patients using its ProTide technology.
NuCana plc (NASDAQ: NCNA) reported its Q4 and full-year 2022 financial results, revealing a cash position of £41.9 million, down from £50.8 million in Q3 2022. The company faced a net loss of £15.2 million for Q4 2022 compared to £13.6 million in Q4 2021, and an annual net loss of £32.0 million, improving from £40.5 million in 2021. Loss per share was £0.29 for Q4 and £0.61 for FY 2022. CEO Hugh S. Griffith highlighted significant progress in their ProTide therapeutics, with important data readouts expected in 2023 for NUC-3373 and NUC-7738. The company anticipates a cash runway through 2025, supporting ongoing clinical trials and development efforts.
NuCana plc (NASDAQ: NCNA) announced that the European Patent Office's Technical Board of Appeal ruled that its European Patent 2955190 is not valid. The decision reverses earlier validations from 2021 and a judgment in the UK on March 21, 2023, which also deemed the patent invalid. Despite this setback, NuCana emphasized that it will not impair its anti-cancer ProTide therapies, as they are protected by other patents. CEO Hugh S. Griffith reassured stakeholders that the company remains financially stable, with all clinical programs on track and multiple data announcements expected in 2023.
FAQ
What is the current stock price of Nucana (NCNA)?
What is the market cap of Nucana (NCNA)?
